Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Shoshana Revel-Vilk, MD, Jeffrey Szer, MBBS, Michal Becker Cohen, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4862.

https://doi.org/10.1182/blood-2019-131013

Published: 2019

Journal Articles

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

David J. Kuter, MD DPhil, Michael Wajnrajch, MD MPA, Betina Hernandez, MD, Rong Wang, MPH, Raul Chertkoff, MD MBA, Ari Zimran, MD

Blood (2018) 132 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2018-99-112660

Published: 2018

Journal Articles

Early Diagnosis of an Infant with Gaucher's Disease Type 3. Case Report

Adriana C. Bello, MD, Rossana Cortez

Blood (2018) 132 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2018-99-110263

Published: 2018

Journal Articles

Health-Related Quality of Life of Twenty-Seven Patients with Gaucher Disease Type I in China

Hongmin Li, PhD, Yuan Li, Zhangbiao Long, MD, Yali Du, Miao Chen, Junling Zhuang, Zhengqing Qiu, Zhao Wang, MD PhD, Bing Han

Blood (2017) 130 (Supplement 1): 4812.

https://doi.org/10.1182/blood.V130.Suppl_1.4812.4812

Published: 2017

Journal Articles

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Pramod Mistry, MD PhD FRCP, Neal J. Weinreb, MD FACP, Julie Batista, ScM, ScD, Hans C. Andersson, MD, Manisha Balwani, MD MS, Thomas Andrew Burrow, MD, Joel Charrow, MD, Paige Kaplan, MB, BCh, Aneal Khan, MD MSc, FCCMG, FRCPC, Priya S. Kishnani, MD MB BS, Edwin H. Kolodny, MD, Barry E. Rosenbloom, MD, C. Ronald Scott, MD

Blood (2016) 128 (22): 4877.

https://doi.org/10.1182/blood.V128.22.4877.4877

Published: 2016

Journal Articles

Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials

Neal J. Weinreb, MD FACP, Timothy M Cox, MD, Elena Lukina, MD, Pramod Mistry, MD PhD FRCP, Jennifer Angell, Sebastiaan Gaemers, MD, M. Judith Peterschmitt, MD

Blood (2015) 126 (23): 884.

https://doi.org/10.1182/blood.V126.23.884.884

Published: 2015

Journal Articles

“Imiglucerase Treatment Associated with Reduction of Bone Claims in Gaucher Patients: Analysis of US Claims Data”

Lubomyra Nalysnyk, MD MPH, Martin Selzer, PhD, Alaa Hamed, MD MPH, MBA, Neal J. Weinreb, MD FACP

Blood (2014) 124 (21): 4837.

https://doi.org/10.1182/blood.V124.21.4837.4837

Published: 2014

Journal Articles

Long Term Outcomes of ERT in Children with Gaucher Disease. Spanish Experience

Marcio M Andrade, MD, Pilar Alfonso, PhD, Pilar Irún, PhD, Javier Dalmau, MD, Jose Luis Barbera, MD, Horacio Cano, MD, María Angeles Fernandez-Galan, MD, Rafael Franco, MD, Inmaculada Garcia, MD, Angela IbaÃ±ez, MD, Francisco Lendinez, MD, Elena Martin-Hernandez, MD, Luis Antonio Sancho-Val, MD, Pablo Sanjurjo, MDPhD, Miguel Pocovi, Prof, Pilar Giraldo, MD PhD

Blood (2014) 124 (21): 4950.

https://doi.org/10.1182/blood.V124.21.4950.4950

Published: 2014

Journal Articles

Assessment of Hematologic and Visceral Parameters in Patients with Type 1 Gaucher Disease in Spain: An Epidemiological Study Using the Therapeutic Goals MAP (Monitor, Action and Progress) Tool ®

Pilar Giraldo, Jordi Perez, Ramiro Núñez, Rafael Fernandez de la Puebla, Elisa Luño, Salvador Saura, Juan Carlos Bureo, Javier de la Serna, Sylvia Plaza, Víctor Navas

Blood (2014) 124 (21): 4963.

https://doi.org/10.1182/blood.V124.21.4963.4963

Published: 2014

Journal Articles

Persistence of Imiglucerase in Cell Compartment Explains Dosing Frequency of Every Two Weeks in Type 1 Gaucher Disease

Juliette Berger, PhD, Marie Vigan, PhD, Jérôme Stirnemann, PD, PhD Professor, Céline Bourgne, PhD, Alexandre Janel, PhD, Nadia Belmatoug, MD, Christian Rose, MD, Monia Bengherbia, Bruno Pereira, France Mentré, MD PhD Professor, Marc G Berger, MD PhD

Blood (2014) 124 (21): 1396.

https://doi.org/10.1182/blood.V124.21.1396.1396

Published: 2014

Journal Articles

Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results

Barry E. Rosenbloom, MD, Timothy M. Cox, MD, Guillermo I. Drelichman, MD, Renata Cravo, MD, Manisha Balwani, MD MS, Thomas Andrew Burrow, MD FAAP, FACMG, Ana Maria Martins, MD PhD, Elena Lukina, MD PhD, Leorah H. Ross, MD PhD, Jennifer Angell, ScM, Judith Peterschmitt, MD

Blood (2014) 124 (21): 1406.

https://doi.org/10.1182/blood.V124.21.1406.1406

Published: 2014

Journal Articles

Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals

Thomas Andrew Burrow, MD, FAAP, FACMG, Manisha Balwani, MD, MS, Timothy M. Cox, MD, Guillermo Drelichman, MD, Renata Cravo, MD, Ana Maria Martins, MD, PhD, Elena Lukina, MD, PhD, Barry E. Rosenbloom, MD, Leorah H. Ross, MD, PhD, Jennifer Angell, ScM, Ana Cristina Puga, MD, PhD

Blood (2013) 122 (21): 3468.

https://doi.org/10.1182/blood.V122.21.3468.3468

Published: 2013

Journal Articles

Replacement Therapy with Imiglucerase Improves Magnetic Resonance Imaging (MRI) Abnormalities in Almost Half Patients with Non-Neuronopathic Form of Gaucher Disease After Twelve Months of Therapy: Results of a Semi-Quantitative MRI Method.

Veroniki Komninaka, Dionysia Kolomodi, Theodore Marinakis, Konstantina Repa, Dimitrios Christoulas, Ersi Voskaridou, Meletios A Dimopoulos, MD, Evangelos Terpos

Blood (2012) 120 (21): 2132.

https://doi.org/10.1182/blood.V120.21.2132.2132

Published: 2012

Journal Articles

Two-Year Safety and Tolerability of Velaglucerase Alfa in Patients with Type 1 Gaucher Disease, Including Patients Switched From Imiglucerase: Phase III Trial HGT-GCB-039 and Extension,

A Mehta, H Ben Turkia, DE Gonzalez, M Kabra, EA Lukina, P Giraldo, I Kisinovsky, A Bavdekar, M-F Ben Dridi, N Gupta, PS Kishnani, EK Sureshkumar, N Barton, N Wang, E Crombez, K Bhirangi, A Zimran

Blood (2011) 118 (21): 3214.

https://doi.org/10.1182/blood.V118.21.3214.3214

Published: 2011

Journal Articles

Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,

Veroniki Komninaka, Theodore Marinakis, Dimitrios Christoulas, Konstantina Repa, Dionysia Kolomodi, Maria Mitropoulou, Maria Gkotzamanidou, Athanasios Papatheodorou, Nikolaos Anagnostopoulos, Meletios Athanasios Dimopoulos, MD, Evangelos Terpos

Blood (2011) 118 (21): 3215.

https://doi.org/10.1182/blood.V118.21.3215.3215

Published: 2011

Journal Articles

Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058

Gregory M Pastores, Barry E Rosenbloom, MD, Neal J Weinreb, Ozlem Goker-Alpan, Rebecca Mardach, Mark Lipson, Jennifer Ibrahim, Gabriel M Cohn, David Zahrieh, Pramod K Mistry

Blood (2011) 118 (21): 1101.

https://doi.org/10.1182/blood.V118.21.1101.1101

Published: 2011

Journal Articles

The Uptake of Recombinant Glucocerebrosidases by Blood Monocytes From Type 1 Gaucher Disease Patients Is Heterogeneous

Juliette Berger, Jérome Stirnemann, MD, PhD, Céline Bourgne, Bruno Pereira, Pascale Pigeon, Djazia Heraoui, Chantal Rapatel, Christian Rose, MD, PhD, Nadia Belmatoug, MD, Marc G Berger, MD, PhD

Blood (2011) 118 (21): 1102.

https://doi.org/10.1182/blood.V118.21.1102.1102

Published: 2011

Journal Articles

How I treat Gaucher disease

Ari Zimran

Blood (2011) 118 (6): 1463–1471.

https://doi.org/10.1182/blood-2011-04-308890

Published: 2011

Journal Articles

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Maria D. Cappellini, MD, Nadia Belmatoug, Alex Cole, Stephan vom Dahl, Patrick Deegan, Jack Goldblatt, Barry E. Rosenbloom, MD, Anna Tylki-Szymañska, Neal J. Weinreb, MD, Ari Zimran, MD, Carla Hollak, MD, PhD

Blood (2010) 116 (21): 4719.

https://doi.org/10.1182/blood.V116.21.4719.4719

Published: 2010

Journal Articles

Analysis of Spanish Experience During Imiglucerase Shortage

Pilar Giraldo, PhD, Pilar Irún, PhD, Pilar Alfonso, PhD, Jaime Dalmau, MD, MAngeles Fernández-Galán, MD, Antonio Figueredo, MD, Angela Ibañez, MD, Jesús M Hernández-Rivas, PhD, Elisa Luño, MD, Francisca Marín-Jimenez, Guillermo Martin-Nuñez, MD, Jorge Montserrat, MD, Javier De la Serna, MD, PhD, Lucia Villalon, MD, Miguel Pocovi, PhD

Blood (2010) 116 (21): 4725.

https://doi.org/10.1182/blood.V116.21.4725.4725

Published: 2010

NARROW

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

Early Diagnosis of an Infant with Gaucher's Disease Type 3. Case Report

Health-Related Quality of Life of Twenty-Seven Patients with Gaucher Disease Type I in China

Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry

Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials

“Imiglucerase Treatment Associated with Reduction of Bone Claims in Gaucher Patients: Analysis of US Claims Data”

Long Term Outcomes of ERT in Children with Gaucher Disease. Spanish Experience

Assessment of Hematologic and Visceral Parameters in Patients with Type 1 Gaucher Disease in Spain: An Epidemiological Study Using the Therapeutic Goals MAP (Monitor, Action and Progress) Tool ®

Persistence of Imiglucerase in Cell Compartment Explains Dosing Frequency of Every Two Weeks in Type 1 Gaucher Disease

Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results

Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals

Replacement Therapy with Imiglucerase Improves Magnetic Resonance Imaging (MRI) Abnormalities in Almost Half Patients with Non-Neuronopathic Form of Gaucher Disease After Twelve Months of Therapy: Results of a Semi-Quantitative MRI Method.

Two-Year Safety and Tolerability of Velaglucerase Alfa in Patients with Type 1 Gaucher Disease, Including Patients Switched From Imiglucerase: Phase III Trial HGT-GCB-039 and Extension,

Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,

Report on the Safety of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease and the Transition From Clinic to Home Infusions During Treatment Protocol HGT-GCB-058

The Uptake of Recombinant Glucocerebrosidases by Blood Monocytes From Type 1 Gaucher Disease Patients Is Heterogeneous

How I treat Gaucher disease

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Analysis of Spanish Experience During Imiglucerase Shortage

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only